Thrombocytosis: an acute-phase reactant, not an adverse reaction to the new beta-lactam antibiotics

Area of Science:

• Pharmacology
• Hematology
• Infectious Diseases

Background:

• Thrombocytosis, an elevated platelet count, has been reported as an adverse drug reaction in up to 30% of patients receiving new beta-lactam antibiotics.
• This association suggests a potential link between antibiotic use and increased platelet levels.

Purpose of the Study:

• To investigate whether thrombocytosis is an adverse drug reaction to antimicrobial agents or an acute-phase reactant.
• To clarify the relationship between antibiotic administration and thrombocytosis in patients with various conditions.

Main Methods:

• A study involving 350 patients with acute noninfectious conditions and infectious diseases.
• Patients were treated with a range of new and old antimicrobial agents.
• Platelet counts were monitored during treatment.

Main Results:

• The study evaluated 350 patients receiving diverse antimicrobial treatments.
• Results indicated that thrombocytosis occurred in patients regardless of the specific antimicrobial agent used.
• The findings suggest thrombocytosis is a physiological response rather than a drug-induced side effect.

Conclusions:

• Thrombocytosis is an acute-phase reactant, a normal physiological response to illness or inflammation.
• The study concludes that thrombocytosis is not an adverse reaction to any specific antimicrobial agent, including beta-lactams.